Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data.
Murthy V, Voter AF, Nguyen K, Allen-Auerbach M, Chen L, Caputo S, Ledet E, Akerele A, Moradi Tuchayi A, Lawhn-Heath C, Wang T, Carducci MA, Pomper MG, Paller CJ, Czernin J, Solnes LB, Hope TA, Sartor O, Calais J, Gafita A. Murthy V, et al. Among authors: solnes lb. J Nucl Med. 2024 Nov 1;65(11):1740-1744. doi: 10.2967/jnumed.124.267816. J Nucl Med. 2024. PMID: 39327018 Clinical Trial.
Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma.
Singh R, Thotakura AK, Alati S, Lisok A, Jiang Z, Merino VF, Minn I, Yadav S, Markowski MC, Ged Y, Pavlovich CP, Singla N, Solnes LB, Gorin MA, Pomper MG, Rowe SP, Banerjee SR. Singh R, et al. Among authors: solnes lb. Front Oncol. 2024 Sep 10;14:1432286. doi: 10.3389/fonc.2024.1432286. eCollection 2024. Front Oncol. 2024. PMID: 39324008 Free PMC article.
Initial Experience with [177Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction.
Gafita A, Voter A, Shesadri S, Spitz A, Marshall CH, Rowe SP, Markowski MC, Pomper MG, Civelek AC, Carducci MA, Denmeade SR, Young J, Pienta KJ, Paller CJ, Solnes LB. Gafita A, et al. Among authors: solnes lb. J Nucl Med. 2024 Nov 1;65(11):1724-1730. doi: 10.2967/jnumed.124.267723. J Nucl Med. 2024. PMID: 39299783
Imaging of Chromophobe Renal Cell Carcinoma with 99mTc-Sestamibi SPECT/CT: Considerations Regarding Risk Stratification and Histologic Reclassification.
Rowe SP, Murtazaliev S, Oldan JD, Kaufmann B, Khan A, Allaf ME, Singla N, Pavlovich CP, De Marzo AM, Baraban E, Gorin MA, Solnes LB. Rowe SP, et al. Among authors: solnes lb. Mol Imaging Biol. 2024 Oct;26(5):768-773. doi: 10.1007/s11307-024-01938-6. Epub 2024 Jul 29. Mol Imaging Biol. 2024. PMID: 39078524
Molecular imaging for non-invasive risk stratification of renal masses.
Rowe SP, Islam MZ, Viglianti B, Solnes LB, Baraban E, Gorin MA, Oldan JD. Rowe SP, et al. Among authors: solnes lb. Diagn Interv Imaging. 2024 Sep;105(9):305-310. doi: 10.1016/j.diii.2024.07.003. Epub 2024 Jul 25. Diagn Interv Imaging. 2024. PMID: 39054210 Review.
104 results